Skip to content

Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure

Telemonitoring Program With Electronic Alerts to Improve Outcomes in the Vulnerable Phase After Hospitalization for Heart Failure: A Pragmatic Clinical Trial TREAT - Vulnerable HF

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05972746
Enrollment
110
Registered
2023-08-02
Start date
2022-10-07
Completion date
2023-11-07
Last updated
2023-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure, Heart Failure

Keywords

telemonitoring, Heart Failure, Vulnerable phase

Brief summary

This pragmatic clinical trial aims to evaluate the impact of a telemonitoring program with an electronic alert system compared to standard treatment on the perception of self-care in patients after hospitalization for decompensated HF at 3 months post-discharge. And secondarily to evaluate its impact on clinical events, NT-proBNP and efficacy and safety to facilitate the use and titration of the recommended drugs in patients with reduced ejection fraction at 90 days.

Interventions

DEVICETelemonitoring with electronic alerts

Patients assigned to this group will receive standard care plus a telemonitoring program.

OTHERStandard of care

Standard of care

Sponsors

Instituto Cardiovascular de Buenos Aires
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Hospitalized for acute heart failure (regardless of the level of left ventricular ejection fraction) within 24 hours of discharge, or with a history of hospitalization for acute HF within 10 days prior to randomization. * Own a smartphone (Smartphone) with internet Ability to speak and read Spanish. * Residence in the metropolitan area of Buenos Aires

Exclusion criteria

* Pregnancy * Alcohol or drug abuse * Kidney failure in hemodialysis, * Inability to use the app (Ex: cognitive impairment, lack of social support, lack of ability to communicate) * Active cancer * Life expectancy less than 1 year * Candidates for care home or institutional end of life * Severe psychiatric illness * Planned cardiac surgery * Patient unable or unwilling to give informed consent to participate.

Design outcomes

Primary

MeasureTime frameDescription
Self-care behavior90 daysThe EHFScBS scale will be used. It consists of a self-administered questionnaire with 12 items addressing various aspects of patient self-care. Each item is scored from 1 (completely agree/always) to 5 (completely disagree/never). The overall score can range from 12 (best self-care) to 60 (worst self-care)

Secondary

MeasureTime frameDescription
NT pro BNP90 days
Medication adherence90 days
Quality of life90 daysThe specific Quality of Life (QoL) related to heart failure will be assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ), which consists of 21 items. Participants rate their perceptions of how heart failure and its treatment affect their daily life on a 6-point Likert scale ranging from 0 (no impairment) to 5 (very impaired). Therefore, lower scores indicate better specific QoL related to heart failure, and a change of 5 points is considered the minimum clinically significant change \[30\]. The MLHFQ yields a total QoL score and separate scores for the physical and emotional well-being sub-scales.
First readmission for heart failure90 days
Total number of readmissions for heart failure90 days
Time to achieve the use of Guideline-Directed Medical Therapy90 days
Proportion of patients with heart failure and reduced ejection fraction who have an increase in the number of Guideline-Directed Medical Therapy90 days

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026